What is VRAX's market cap?

$1.07M, based on the Nov 6 close of $0.79.

Does Virax Biolabs Group Limited pay a dividend?

No regular cash dividend has been paid in the last year.

How much of VRAX is sold short?

9.0K shares, 1.2% of float, as of Oct 15, 2026.

NASDAQ · VRAX

Virax Biolabs Group Limited Ordinary Shares (VRAX)

$0.7919−32.89%

Close Nov 6, 2026 · split-adjusted

Nov 5, 2026$1.18▼ 90.77% in range

Nov 5, 2025Low $1.06 · High $84.38Nov 5, 2026

What changed · written from our data

As of Nov 6, 2026

Virax Biolabs Group Limited closed at $0.79 on Nov 6, down 32.89%, within 0.0% of its 52-week closing low. Volume of 1.1M shares was 1.44× its 20-day average (above normal).

Split-adjusted performance: -60.2% over one month, -81.5% over six months, -93.8% over one year.

Short interest was 9.0K shares at the Oct 15 settlement, up 35.2% from the prior report (1.2% of float, 1.0 days to cover).

Market cap$1.1M1.3M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range0.79 – 84.38−99.1% from high

Volume1.1M1.44× 20-day avg

Volatility · 60d118.4%Annualised

Short % of float1.2%1.0 days to cover

Net cash$6.4MCash $6.4M

Next earnings—Not scheduled

Split-adjusted performance

1W −34.6%1M −60.2%3M −72.5%6M −81.5%YTD −90.8%1Y −93.8%3Y −98.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within industry

Not enough peers to rank

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Short interest

Details →

Shares short9.0K+35.2% vs prior

Days to cover1.0Settled Oct 15

% of float1.2%

Short vol. 10d61.4%of daily volume

News about Virax Biolabs Group Limited

All news →

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesBenzinga · May 26, 2026▲ Positive

Quick answers

What does Virax Biolabs Group Limited do?: Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling.
What is VRAX's market cap?: $1.07M, based on the Nov 6 close of $0.79.
Does Virax Biolabs Group Limited pay a dividend?: No regular cash dividend has been paid in the last year.
How much of VRAX is sold short?: 9.0K shares, 1.2% of float, as of Oct 15, 2026.

About Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

26 employeesListed Jul 21, 2022viraxbiolabs.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology